Effects of tirzepatide on cardiac injury and kidney function Treatment with tirzepatide resulted in a significant reduction in myocardial injury reflected by high-sensitivity troponin T as compared with placebo at both 24 and 52 weeks (ETD 24 weeks 9.8% (95% CI 16.0 to 3.3), P = 0.004, 52 weeks 10.4% (95% CI 16.7 to 3.6), P = 0.003), with no significant effect at 12 weeks (Fig
It also increases the activity of genes like ALDH2 that help to detoxify the system [13]
The post says no large randomized controlled trials specifically evaluate safety in active ulcerative colitis, that most trials excluded patients with inflammatory bowel disease, and that gastroenterology case reports have raised concerns about symptom flares
Always follow your doctors instructions carefully
Individual receptor sensitivity, baseline insulin resistance, genetic polymorphisms in GLP-1 and GIP receptors, and prior treatment duration all affect response
For a complete visual reference of how semaglutide doses translate across different vial concentrations, see our semaglutide 5mg/mL dosage chart and units-to-mg conversion guide